Andrew John O
CIK: 0002103158
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PLYX
Polaryx Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About O Andrew John
O Andrew John (SEC CIK 0002103158) files insider reports with the SEC as Chief Investment Officer of Polaryx Therapeutics, Inc. (PLYX).
Signal8 holds 1 ownership filing by O Andrew John, a Form 3, filed on Jan 29, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on O Andrew John's filings is in PARAMUS, NJ.
Other insiders filing for Polaryx Therapeutics, Inc. (PLYX)
- Yang Alex Keun Mo, Chief Executive Officer
- Landis G. Michael, Chief Financial Officer
- Braun III Francis A, Director
- Bollinger Lisa, Chief Medical Officer
- Ryan Charles S., Director
- Berger Mitchel, Director